Industries > Pharma > Global Biosimilar Monoclonal Antibodies Forecast 2017-2027

Global Biosimilar Monoclonal Antibodies Forecast 2017-2027

Biosimilar Versions of Infliximab, Rituximab, Trastuzumab, Adalimumab, Bevacizumab and Abciximab

PUBLISHED: 19 May 2017
PAGES: 204
PRODUCT CODE: PHA0194

Clear
WOOCS 2.2.1

The global biosimilar monoclonal antibodies market is expected to grow at a CAGR of 9.6% in the second half of the forecast period. The market is expected to grow at a CAGR of 23.8% from 2015-2027. The market is estimated at $4.2bn in 2020 and $7.9bn in 2027.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 204-page report you will receive 72 tables and 72 figures – all unavailable elsewhere.

The 204-page report provides clear detailed insight into the global biosimilar monoclonal antibodies market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

Global Biosimilar Monoclonal Antibodies Market forecasts from 2017-2027

• Along with revenue prediction for the overall world market for biosimilar monoclonal antibodies, our investigation shows forecasts to 2027 for the market segmented by compound:
– Infliximab
– Rituximab
– Abciximab
– Trastuzumab
– Adalimumab
– Bevacizumab

• This report also shows revenue to 2027 for individual biosimilar mAb products in the market:
– Remsima/Inflectra
– Infimab
– Reditux
– BI695500
– CT-P10
– BI695501
– FKB327
– FKB238
– Mabtas
– AcellBia
– Maball
– Clotinab
– Abcixirel
– BCD-022
– BCD-021
– Herzuma
– CANMAB/Hertraz

• Our analyses show individual revenue forecasts to 2027 for these regional and national markets:
– The US Biosimilar mAb Market
– Japanese Biosimilar mAb Market
– EU5 Biosimilar mAb Markets
– BRIC and South Korea Biosimilar mAb Markets
– Rest of the World Biosimilar mAb Market

Global Biosimilar Monoclonal Antibodies Forecast 2017-2027

• This report profiles 10 leading companies either with biosimilar mAbs already on the market or in the pipeline

• Our study discusses strengths, weaknesses, opportunities and threats affecting the biosimilar monoclonal antibodies market

Visiongain’s study is intended for anyone requiring commercial analyses for the biosimilars monoclonal antibodies market. You find data, trends and predictions.

Buy our report today Global Biosimilar Monoclonal Antibodies Forecast 2017-2027: Biosimilar Versions of Infliximab, Rituximab, Trastuzumab, Adalimumab, Bevacizumab and Abciximab.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Global Biosimilar Monoclonal Antibodies Forecast 2017-2027


Download sample pages

Complete the form below to download your free sample pages for Global Biosimilar Monoclonal Antibodies Forecast 2017-2027


Latest Pharma news

Visiongain Publishes Liposomal Drug Delivery Devices Market Report 2022-2032

Global liposomal drug delivery devices market is projected to grow at a CAGR of 10.69% by 2032.

21 June 2022

READ

Visiongain Publishes Nanotechnology in Drug Delivery Market Report 2022-2032

The global nanotechnology in drug delivery market was valued at US$53.0 billion in 2021 and is projected to grow at a CAGR of 18.7% during the forecast period 2022-2032.

20 June 2022

READ

Visiongain Publishes Respiratory Drug Delivery Technologies Market Report 2022-2032

The global respiratory drug delivery technologies market was valued at US$59.51 billion in 2022 and is projected to grow at a CAGR of 7.31% during the forecast period 2022-2032.

15 June 2022

READ

Visiongain Publishes Artificial Intelligence (AI) in Drug Discovery Market Report 2022-2032

The global artificial intelligence (AI) in drug discovery market was valued at US$791 million in 2021 and is projected to grow at a CAGR of 30.7% during the forecast period 2022-2032.

14 June 2022

READ

Categories